Drug updated on 11/17/2023
|Injection (intramuscular; 50 mg/0.5 mL in a single-dose pre-filled syringe)
|Respiratory syncytial virus (RSV) F protein-directed fusion inhibitor
| Ongoing and
- For the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Product Monograph / Prescribing Information
|Beyfortus (nirsevimab-alip) Prescribing Information.
|Sanofi Pasteur, Inc., Swiftwater, PA 18370 USA
Systematic Reviews / Meta-Analyses
|The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.
|Frontiers in Pediatrics
|Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
|JAMA Network Open